In recent years, research on stem cell therapy in the field of lung transplantation has gradually increased, demonstrating its potential in improving the outcomes of lung transplantation. As a treatment option for end-stage lung diseases, lung transplantation faces challenges such as scarcity of donor organs, postoperative complications and rejection. Stem cells, with their self-renewal and multi-directional differentiation capabilities, have emerged as strong candidates for alternative or adjunctive treatments. Current studies show that embryonic stem cells and umbilical cord mesenchymal stem cells play significant roles in lung tissue regeneration and immune regulation. However, stem cell therapy still needs to overcome issues such as the selection of cell sources, low survival rates after transplantation and unclear long-term efficacy in clinical applications. Future research should focus on exploring new stem cell sources, improving transplantation techniques and establishing efficacy evaluation systems.

Schizophrenia is a chronic and debilitating mental disorder.Around 20%to 40%of patients do not respond well to normal antipsychotic medication,and are ultimately diagnosed with treatment-resistant schizophrenia(TRS),representing the most severe and challenging form of schizophrenia.Currently,clozapine is the standard treatment for TRS.Early identification and standardized treatment can be beneficial to patients with TRS by controlling acute-phase symptoms as soon as possible,reducing suicidal rate and improving their quality of life.Under the guidance of the Steering Committee,this consensus was formed after multiple discussions by 30 psychiatric experts and anonymous Delphi surveys including 17 consensus opinions on treatment-resistant schizophrenia,which cover risk factors and prevention,diagnosis and evaluation,standardized clozapine treatment and management of adverse reactions,treatment regimens for clozapine resistance and intolerance,and psychosocial intervention,etc.The consensus-making process also incorporated evidence-based medicine to help standardize and guide diagnosis and treatment for adults with TRS in China.

Objective To investigate the expression levels and diagnostic value of long noncoding RNA(LncRNA)GUSBP3 and LncRNA SAM4 in peripheral blood of Kazakh type 2 diabetes mellitus(T2DM)patients in Xinjiang.Methods From January to September 2019,Kazakh T2DM patients in The First Affiliated Hospital of Shihezi University were recruited through outpatient or inpatient department(T2DM group,n=30).And 30 healthy people were selected as normal control(NC)group during the same period.The general data,biochemical indicators and differentially expressed LncRNA levels were compared between the two groups.Spearman correlation analysis was used to analyze the correlation between the target genes and each index.Logistic regression was used to analyze the influencing factors for T2DM.Receiver operating characteristic(ROC)curve was used to evaluate the diagnostic value of target genes.Results The differentially expressed LncRNA were LncRNA GUSBP3 and LncRNA SAM4 in the two groups.DBP,FPG,HbA1c,fructosamine,FIns,islet β cell function index,serum creatinine(Scr),LncRNA GUSBP3 and LncRNA SAM4 were higher in the T2DM group than in the NC group(P<0.05).Spearman correlation analysis showed that the expression of LncRNA GUSBP3 was positively correlated with Scr and serum uric acid(SUA)(r=0.328,0.322,P<0.05),and negatively correlated with FIns(r=-0.295,P<0.05).The expression of LncRNA SAM4 was positively correlated with SUA(r=0.275,P<0.05)and negatively correlated with LDL-C(r=-0.212,P<0.05).Logistic regression analysis showed that DBP(OR 1.175,95%CI 1.011～1.367),FIns(OR 0.852,95%CI 0.739～0.982),LncRNA GUSBP3(OR 0.378,95%CI 0.149～0.958)was influencing factors for T2DM in Kazakh population.The area under the ROC curve of LncRNA GUSBP3 was 0.789 for T2DM diagnosis.Conclusions The expression levels of LncRNA GUSBP3 and LncRNA SAM4 were higher in Kazakh patients with T2DM than in healthy people,and their expression levels are related to some biochemical indicators.DBP,FIns and LncRNA GUSBP3 are the influencing factors for T2DM in Kazakh population.LncRNA GUSBP3 may be a biomarker for the diagnosis of T2DM in Kazakh in Xinjiang.

Lung transplantation is currently the only recognized effective treatment for end-stage lung disease and has improved the quality of life for patients. However, lung transplantation still faces many challenges, including rejection, infection, post-transplant acute kidney injury, post-transplant diabetes mellitus, ischemia-reperfusion injury and donor shortage, etc. Chinese lung transplantation scholars made a series of important progress in the field of clinical research in 2024, focusing on the study and solution of the above problems, and providing new ideas for lung transplantation surgery. This article systematically reviews the clinical research and technological innovation in the field of lung transplantation in 2024, summarizes the achievements of clinical research in the field of lung transplantation in China in 2024, and aims to providing new directions and strategies for future research.

Lung transplantation is the optimal treatment for end-stage lung diseases and can significantly improve prognosis of the patients. However, postoperative complications such as infection, rejection, ischemia-reperfusion injury, and other challenges (like shortage of donor lungs) , limit the practical application of lung transplantation in clinical practice. Chinese research teams have been making continuous efforts and have achieved breakthroughs in basic research on lung transplantation by integrating emerging technologies and cutting-edge achievements from interdisciplinary fields, which has strongly propelled the development of this field. This article will comprehensively review the academic progress made by Chinese research teams in the field of lung transplantation in 2024, with a focus on the achievements of Chinese teams in basic research on lung transplantation. It aims to provide innovative ideas and strategies for key issues in the basic field of lung transplantation and to help China's lung transplantation cause reach a higher level.

Objective:To investigate the preventive and therapeutic effects and mechanisms of Dachaihu decoction(DCD)on dextran sodium sulfate(DSS)-induced ulcerative colitis(UC)and liver injury in mice,as well as the association between DCD benefits and gut microbiota modulation.Methods:Mice were treated with DCD(20.10 and 10.05 g/kg)for 2 weeks,with free access to drinking water containing 3%DSS in the second week to induce UC.Histopathological examination,RT-qPCR and 16S rRNA sequencing were used to investigate the effect of DCD on UC mice.Results:DCD pretreatment significantly alleviated weight loss,bloody diarrhea with mucus,histopathological abnormalities of the colon,and colon shortening in mice with DSS-induced UC.In addition,DCD pretreat-ment significantly upregulated the levels of Occludin,ZO-1,and MUC-2 in the colon and protected the intestinal barrier of mice.DCD pretreatment also alleviated inflammatory cell infiltration in the colon and the liver and significantly reduced the expression levels of the proinflammatory factors such as IL-1β,IL-6,TNF-α,iNOS,COX-2,and NLRP3,thereby exerting a protective effect against UC and liver injury.It should be noted that DCD corrected gut micro-biota imbalance in UC mice by enriching probiotic bacteria such as Lactobacillus and Bifidobacterium and reducing harmful bacteria such as Norank_f_Desulfovibrionaceae and Escherichia-Shigella.Conclusion:DCD can alleviate DSS-induced UC and exert a liver-protecting effect by protecting intestinal barrier,inhibiting inflam-mation,and regulating gut microbiota.

Objective:To systematically evaluate the disease experience and inner needs of young and middle-aged patients with end-stage renal disease, so as to provide evidence for medical personnel to pay more attention to the mental health of this population and give personalized care.Methods:The qualitative studies on the real experience, psychological feeling and experience of young and middle-aged patients with end-stage renal disease were searched by PsycInfo, PubMed, Embase, CINAHL, Web of Science, China National Knowledge Network, Wanfang, VIP and China Biomedical Literature Database. The retrieval period was from the establishment of the database to April 20, 2024. Joanna Briggs Institute Evidence-based Health Care Center Evaluation criteria (2016 edition) were used to evaluate the literature quality, and the results were summarized and integrated by aggregative meta-integration method.Results:A total of 10 studies were included, and 47 clear findings were extracted and classified into 10 new categories, which were combined into 4 integrated results: the phased changes of patients′ real experience at all levels of body, mind and society, impairment of their own and family role functions, desire for support and lack of autonomy in decision-making, and reconstruction of positive attitude and future outlook in the face of disease.Conclusions:Nursing staff should pay attention to and understand the psychosocial conditions of young and middle-aged patients with end-stage renal disease, timely provide targeted psychological support and help to enhance their confidence in treatment, better return to work and society, and improve their quality of life.

Schizophrenia is a chronic and debilitating mental disorder.Around 20%to 40%of patients do not respond well to normal antipsychotic medication,and are ultimately diagnosed with treatment-resistant schizophrenia(TRS),representing the most severe and challenging form of schizophrenia.Currently,clozapine is the standard treatment for TRS.Early identification and standardized treatment can be beneficial to patients with TRS by controlling acute-phase symptoms as soon as possible,reducing suicidal rate and improving their quality of life.Under the guidance of the Steering Committee,this consensus was formed after multiple discussions by 30 psychiatric experts and anonymous Delphi surveys including 17 consensus opinions on treatment-resistant schizophrenia,which cover risk factors and prevention,diagnosis and evaluation,standardized clozapine treatment and management of adverse reactions,treatment regimens for clozapine resistance and intolerance,and psychosocial intervention,etc.The consensus-making process also incorporated evidence-based medicine to help standardize and guide diagnosis and treatment for adults with TRS in China.

Objective To investigate the expression levels and diagnostic value of long noncoding RNA(LncRNA)GUSBP3 and LncRNA SAM4 in peripheral blood of Kazakh type 2 diabetes mellitus(T2DM)patients in Xinjiang.Methods From January to September 2019,Kazakh T2DM patients in The First Affiliated Hospital of Shihezi University were recruited through outpatient or inpatient department(T2DM group,n=30).And 30 healthy people were selected as normal control(NC)group during the same period.The general data,biochemical indicators and differentially expressed LncRNA levels were compared between the two groups.Spearman correlation analysis was used to analyze the correlation between the target genes and each index.Logistic regression was used to analyze the influencing factors for T2DM.Receiver operating characteristic(ROC)curve was used to evaluate the diagnostic value of target genes.Results The differentially expressed LncRNA were LncRNA GUSBP3 and LncRNA SAM4 in the two groups.DBP,FPG,HbA1c,fructosamine,FIns,islet β cell function index,serum creatinine(Scr),LncRNA GUSBP3 and LncRNA SAM4 were higher in the T2DM group than in the NC group(P<0.05).Spearman correlation analysis showed that the expression of LncRNA GUSBP3 was positively correlated with Scr and serum uric acid(SUA)(r=0.328,0.322,P<0.05),and negatively correlated with FIns(r=-0.295,P<0.05).The expression of LncRNA SAM4 was positively correlated with SUA(r=0.275,P<0.05)and negatively correlated with LDL-C(r=-0.212,P<0.05).Logistic regression analysis showed that DBP(OR 1.175,95%CI 1.011～1.367),FIns(OR 0.852,95%CI 0.739～0.982),LncRNA GUSBP3(OR 0.378,95%CI 0.149～0.958)was influencing factors for T2DM in Kazakh population.The area under the ROC curve of LncRNA GUSBP3 was 0.789 for T2DM diagnosis.Conclusions The expression levels of LncRNA GUSBP3 and LncRNA SAM4 were higher in Kazakh patients with T2DM than in healthy people,and their expression levels are related to some biochemical indicators.DBP,FIns and LncRNA GUSBP3 are the influencing factors for T2DM in Kazakh population.LncRNA GUSBP3 may be a biomarker for the diagnosis of T2DM in Kazakh in Xinjiang.

Objective:To systematically evaluate the disease experience and inner needs of young and middle-aged patients with end-stage renal disease, so as to provide evidence for medical personnel to pay more attention to the mental health of this population and give personalized care.Methods:The qualitative studies on the real experience, psychological feeling and experience of young and middle-aged patients with end-stage renal disease were searched by PsycInfo, PubMed, Embase, CINAHL, Web of Science, China National Knowledge Network, Wanfang, VIP and China Biomedical Literature Database. The retrieval period was from the establishment of the database to April 20, 2024. Joanna Briggs Institute Evidence-based Health Care Center Evaluation criteria (2016 edition) were used to evaluate the literature quality, and the results were summarized and integrated by aggregative meta-integration method.Results:A total of 10 studies were included, and 47 clear findings were extracted and classified into 10 new categories, which were combined into 4 integrated results: the phased changes of patients′ real experience at all levels of body, mind and society, impairment of their own and family role functions, desire for support and lack of autonomy in decision-making, and reconstruction of positive attitude and future outlook in the face of disease.Conclusions:Nursing staff should pay attention to and understand the psychosocial conditions of young and middle-aged patients with end-stage renal disease, timely provide targeted psychological support and help to enhance their confidence in treatment, better return to work and society, and improve their quality of life.